Is Another Biotech Buyout on the Horizon?
It's been an exciting year so far for biotech acquisitions: Perrigo made a surprising move for Elan, AstraZeneca has been boosting its pipeline with a series of purchases, and Amgen's recent buyout of oncology specialist Onyx revived investor enthusiasm in the second biggest biotech company in the world. And it doesn't look like this trend is going to stop any time soon.
At the end of last week, a Bloomberg article revealed that Shire and pharmaceutical giant Sanofi may be circling ViroPharma . The the following video, from The Motley Fool's health care show Market Checkup, analysts David Williamson and Max Macaluso take a close look at ViroPharma and discuss the recent interest in this small biotech company.
Stocks for a Longer Time Horizon
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.
The article Is Another Biotech Buyout on the Horizon? originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.